In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding ...

While there was no difference in the rate of the primary composite end point or its separate components between those who received prasugrel and those who got clopidogrel in the first year of the ...

Overall, prasugrel may be superior to the approved dose of the older drug, clopidogrel (Plavix), in many cases. But more doctors have been using an initial, higher-than-standard dose of ...

Prior to the approval of prasugrel, clopidogrel was considered the agent of choice due to safety concerns associated with ticlopidine. A randomized controlled trial comparing prasugrel and ...

Clopidogrel requires transformation into an ... in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38.

Presented at EuroPCR 2025, the results of the 4D-ACS trial show how a shorter antiplatelet regimen after PCI could reduce ...

Moreover, the findings suggest that the lower dose yields bleeding rates similar to maintenance clopidogrel without compromising prasugrel’s efficacy advantage over the older thienopyridine. Results ...

Those results showed that the number of patients who had subsequent non-fatal heart attacks was reduced from 9.1% in the Plavix arm to 7% in those who took Effient. However, while the numbers of ...

The pharmacy benefits manager Medco announced that it would run its own head-to-head trial comparing Effient with Plavix, the big-selling clot-buster that's not only cheaper than Effient now ...